Deucravacitinib vs Placebo in Moderate-to-Severe Hidradenitis Suppurativa: A Pilot Study

Name: Deucravacitinib vs Placebo in Moderate-to-Severe Hidradenitis Suppurativa: A Pilot Study
Creator: Martina Porter
Published: 2026-08-28T09:46:57.953Z
Keywords: Dermatology, Clinical Trial, Tyrosine Kinase Inhibitor, Immunomodulator, Hidradenitis Suppurativa

Porter, Martina; Doroudian Tehrani, Maneli; Ashina, Nazrin; Wafae, Bruna; Tran, Thao-Mary; Truong, Hoang; Sweet, William; Gao, Julia; Salian, Prerna; Kimball, Alexa

doi:10.17632/znnbpf36jf.1

Deucravacitinib vs Placebo in Moderate-to-Severe Hidradenitis Suppurativa: A Pilot Study

Published: 28 August 2026| Version 1 | DOI: 10.17632/znnbpf36jf.1

Contributors:

Martina Porter,

, Nazrin Ashina, Bruna Wafae, Thao-Mary Tran, Hoang Truong, William Sweet, Julia Gao, Prerna Salian, Alexa Kimball

Description

Supplemental material accompanying the manuscript “Deucravacitinib vs Placebo in Moderate-to-Severe Hidradenitis Suppurativa: A Pilot Study,” accepted for publication in JAAD International.

Files

Institutions

Beth Israel Deaconess Medical Center
Massachusetts, Boston

Deucravacitinib vs Placebo in Moderate-to-Severe Hidradenitis Suppurativa: A Pilot Study

Description

Files

Institutions

Categories

Licence